Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of generalised myasthenia gravis (gMG) patients after 52 weeks in a Phase III trial. Results from the company’s ...

(RTTNews) - Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing ...

Amgen discovers, develops ... with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best pharma stocks to buy according to hedge funds. The US pharmaceutical sector is ...

Deep-pocketed investors have adopted a bullish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

which it says reflects “significant payer utilisation management restrictions in the US and limited market access in Europe.” Amgen reported a slightly healthier $40 m for Repatha in the third ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab ...